We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MOXONIDINE SCP, MOXONIDINE TLB, APO-MOXONIDINE, MOXONIDINE RMB, MOXONIDINE AJS, MOXONIDINE SANDOZ (Southern Cross Pharma Pty Ltd)
Product name
MOXONIDINE SCP, MOXONIDINE TLB, APO-MOXONIDINE, MOXONIDINE RMB, MOXONIDINE AJS, MOXONIDINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
157 working days (255)
Active ingredients
moxonidine
Registration type
New generic medicine
Indication
MOXONIDINE SCP, MOXONIDINE TLB, APO-MOXONIDINE, MOXONIDINE RMB, MOXONIDINE AJS, MOXONIDINE SANDOZ (tablets) is indicated for the treatment of hypertension.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine